Biovica International AB

Biovica International AB is a Swedish biotechnology company founded in 2009, focused on enhancing cancer therapy monitoring and prediction through innovative blood-based biomarker assays. The company primarily targets breast cancer, aiming to improve patient outcomes and reduce healthcare costs by equipping oncologists with precise tools for treatment management. The flagship product, the DiviTum® TKa test, is a blood test that measures cell proliferation from solid tumors. This test enables real-time monitoring of disease progression and treatment response, particularly for therapies like CDK4/6 inhibitors and palbociclib used in metastatic breast cancer. By allowing oncologists to assess treatment effectiveness early and continuously, the DiviTum® TKa test supports informed clinical decisions. Biovica collaborates with leading cancer institutes, research groups, and pharmaceutical companies, engaging in numerous projects and studies that highlight its strong clinical validation. The company is committed to transforming cancer care management through its biomarker-based tests, guided by values of collaboration, innovation, and ethical responsibility.

• Employees 26
• Founded 2009
• Annual Revenue $894000
• Total Funding $23586040